section name header

Pronunciation

brex-AN-oh-lone

Classifications

Therapeutic Classification: antidepressants

Pharmacologic Classification: corticosteroids, gamma aminobutyric acid gaba enhancers

Indications

REMS


Action

  • Although not fully understood, thought to be related to positive allosteric modulation of GABA-A receptors.
Therapeutic effects:
  • Reduction in depressive symptoms.

Pharmacokinetics

Absorption: IV administration results in complete absorption.

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Extensively metabolized via keto-reduction, glucuronidation, and sulfation to inactive metabolites. Primarily excreted in feces (47%) and urine (42%) as metabolites.

Half-Life: 9 hr.

Time/Action Profile

(reduction in depressive symptoms)

ROUTEONSETPEAKDURATION
IV1–2 hr60–72 hrAt least 30 days





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: tachycardia

Derm: flushing

GI: dry mouth, diarrhea, dyspepsia, oropharyngeal pain

Neuro: dizziness, presyncope, sedation, vertigo, altered consciousness, loss of consciousness, SUICIDAL THOUGHTS/BEHAVIORS

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Zulresso

Contr. Subst. Schedule

Schedule IV (C-IV)